IFX-201 / Infinimmune - LARVOL DELTA

Infinimmune Raises $75 Million Series A Financing to Advance Pipeline of Human-Derived Antibodies for Atopic Dermatitis and Inflammatory Disease (Businesswire) - "The financing will accelerate clinical development of Infinimmune’s two lead programs in atopic dermatitis, support advancement of additional programs leveraging human-first biology to address unmet clinical needs, and enable continued deployment of the company's Anthrobody discovery platform. Infinimmune will initiate first-in-human studies for its two lead programs in 2027. Infinimmune is advancing a pipeline of fully human antibodies...including: (i) IFX-101 - a first and best-in-class monoclonal antibody targeting IL-22; (ii) IFX-201 - a best-in-class monoclonal antibody targeting IL-13."

Financing • First-in-human • New trial • Atopic Dermatitis